Leap Therapeutics (LPTX) Stock Price Down 23.1%
Leap Therapeutics (NASDAQ:LPTX) dropped 23.1% during mid-day trading on Monday . The stock traded as low as $6.94 and last traded at $7.49. Approximately 710,923 shares changed hands during trading, an increase of 500% from the average daily volume of 118,532 shares. The stock had previously closed at $9.74.
LPTX has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Tuesday, January 23rd. HC Wainwright initiated coverage on shares of Leap Therapeutics in a research note on Thursday. They set a “buy” rating and a $12.50 target price on the stock. Finally, ValuEngine raised shares of Leap Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 22nd.
The company has a market capitalization of $141.24, a PE ratio of -2.94 and a beta of -0.42.
A hedge fund recently bought a new stake in Leap Therapeutics stock. Sabby Management LLC bought a new position in shares of Leap Therapeutics (NASDAQ:LPTX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned approximately 0.72% of Leap Therapeutics as of its most recent SEC filing. Institutional investors own 2.77% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Leap Therapeutics (LPTX) Stock Price Down 23.1%” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2018/04/16/leap-therapeutics-lptx-stock-price-down-23-1.html.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.